Validea Detailed Fundamental Analysis

Pfizer (PFE) has received a top 100% rating from Validea's 'Earnings Yield Investor' model, based on Joel Greenblatt's historically outperforming 'Magic Formula' strategy. This assessment identifies PFE as a large-cap value stock in the Biotechnology & Drugs sector, indicating strong underlying fundamentals and valuation by meeting criteria for high return on capital and earnings yields. The perfect score signals significant investment interest from a proven quantitative approach.

Analysis

Pfizer (PFE) has achieved a maximum 100% rating from Validea's investment model based on Joel Greenblatt's "Magic Formula," a quantitative strategy focused on identifying companies with high earnings yields and high returns on capital. This top score, which signifies strong interest from the model, positions PFE as a compelling large-cap value stock within the Biotechnology & Drugs industry. The rating is based on the firm's underlying fundamentals and current valuation. Interestingly, while the detailed criteria list both Earnings Yield and Return on Tangible Capital as "NEUTRAL," the final weighted ranking under the proprietary formula is a "PASS" with a perfect score. This suggests that the combination and specific weighting of these factors in Greenblatt's model, which has a history of significant back-tested outperformance, find Pfizer's profile highly attractive, even if individual components do not receive the highest possible standalone rating.

Key Decisions for Investors

• Investors with a value-oriented or GARP (Growth at a Reasonable Price) mandate should consider PFE a candidate for further due diligence, as its 100% score on the historically successful Greenblatt model signals a potentially attractive combination of quality and value.
• Quantitative investors should note PFE's perfect screening on factors of high earnings yield and return on capital, suggesting the stock may be a strong candidate for inclusion in factor-based portfolios.
• It is prudent to investigate the underlying metrics that resulted in the 'NEUTRAL' ratings for earnings yield and return on capital to fully understand the drivers behind the model's highly favorable composite score before committing capital.